药品审批
药物开发
医学
药品
小儿肿瘤学
抗癌药
肿瘤科
药理学
重症监护医学
癌症
内科学
作者
Joshua Donaldson,Marjilla Seddiq,Michael Fusco,Shyamli Singla,Gulsum E. Pamuk,Rosa J. Lee-Alonso,Bronwyn D. Mixter,Kirsten B. Goldberg,Laleh Amiri‐Kordestani,R. Angelo de Claro,Nicole Drezner,Nicole Gormley,Bindu Kanapuru,Steven J. Lemery,Lola A. Fashoyin-Aje,Nicholas C. Richardson,Harpreet Singh,Daniel L. Suzman,Marc R. Theoret,Paul G. Kluetz,Richard Pazdur
出处
期刊：Cancer Discovery
[American Association for Cancer Research]
日期：2023-12-12
卷期号：13 (12): 2515-2524
标识
DOI：10.1158/2159-8290.cd-23-1226
摘要
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI
rocky15
Solomon
shinysparrow
cctv18
寻道图强
OCDer
gjww
坚强的广山
沫豆
Maestro_S
阿大呆呆
江泽
寒雨
酸化土壤改良
Cindy
深情安青
Lucas
领导范儿
CWNU_HAN
Caesar
皖公网安备34019202002308
